WATCH LIVE
timothy sykes logo
Guardant Health Stock Climbs As FDA Win Fuels Bullish Targets Thumbnail
G Google News

Guardant Health Stock Climbs As FDA Win Fuels Bullish Targets

JACK KELLOGG•UPDATED JUL. 1, 2026, 2:34 PM ET
Reviewed by Ellis Hobbsand Fact-checked by Matt Monaco

Guardant Health Inc. surged as positive clinical and regulatory developments fueled bullish sentiment, and stocks have been trading up by 13.05 percent.

Key Takeaways

  • The FDA approved Guardant360 CDx as a companion diagnostic for HER2‑mutant advanced lung cancer, marking the 27th indication on the Guardant360 platform.
  • RBC launched coverage on Guardant Health (GH) with an Outperform rating and a $185 target, pointing to a large, underpenetrated tumor profiling market.
  • Evercore ISI, Mizuho, Goldman Sachs, Wolfe, Bernstein, and Guggenheim all boosted ratings or targets on GH, leaning into new FDA and pricing catalysts.
  • GH shares traded more than 1% higher premarket on the FDA news, signaling traders are already pricing in stronger test demand.
  • June 2026 insider sales, including a 100,000‑share sale by Co‑CEO Helmy Eltoukhy, add a note of caution even as he retains a sizable stake.

Candlestick Chart

Live Update At 14:32:45 EDT: On Wednesday, July 01, 2026 Guardant Health Inc. stock [NASDAQ: GH] is trending up by 13.05%! Discover the key drivers behind this movement as well as our expert analysis in the detailed breakdown below.

Quick Financial Overview

Guardant Health (GH) has been trading like a momentum name. The daily chart shows a strong climb from a close near $124.89 on 2026/06/08 to $169.61 on 2026/07/01. That is a steep multi‑week trend, with GH repeatedly putting in higher lows from the mid‑$120s to the high‑$160s. For short‑term traders, that kind of staircase pattern usually screams “buy the dip, sell the rip” until the trend breaks.

Intraday, GH has shown controlled strength. On the latest session, the stock opened around $160.76, dipped toward $156.16, then powered to an intraday high of $170.96 before closing near $169.61. The five‑minute candles show steady bids stepping up from the low‑$160s midday into the high‑$160s and low‑$170s into the close. That’s classic accumulation, not random chop.

More Breaking News

Fundamentally, GH remains a high‑growth, loss‑making diagnostics player. Revenue over the last year ran about $982.0M, with a strong 64.9% gross margin but ugly operating losses: EBIT margin around -39.8% and profit margin about -40.1%. Return on assets is deeply negative, yet the balance sheet is liquid, with a current ratio of 4.7 and more than $989.3M in cash as of 2026/03/31. For traders, GH is a story and catalyst stock, not a value name; price action will track news and volume more than classic earnings metrics.

Why Traders Are Watching Guardant Health Now

Guardant Health is on a run because the story just got bigger. The FDA signed off on Guardant360 CDx as a companion diagnostic for Boehringer Ingelheim’s HERNEXEOS in HER2‑mutant advanced non‑small cell lung cancer. That move gives the Guardant360 platform its 27th companion diagnostic indication and further locks GH into day‑to‑day precision oncology workflows. In plain terms: more doctors using Guardant360, more tests, more revenue visibility.

Traders saw an immediate reaction. GH traded more than 1% higher premarket after the approval, and the move helped launch the stock into its current uptrend. But the real fuel has been the wave of bullish Wall Street calls that followed.

RBC Capital initiated Guardant Health with an Outperform rating and a street‑high $185 target, framing GH as a structural growth story in an underpenetrated metastatic cancer testing market. Mizuho pushed its target from $135 to $175, leaning on the same FDA Guardant360 catalyst plus Shield‑related growth and profitability tailwinds. Evercore ISI jumped from In Line to Outperform and hiked its target to $160, stressing favorable G360 pricing and a volume inflection from 2027 onward.

Then came the reinforcement. Goldman Sachs started GH at Buy with a $165 target, calling the company a leader in therapy selection thanks to its 740‑gene G360 CDx panel, tissue testing momentum, and an upcoming MRD launch. Wolfe Research labeled Guardant Health its top idea in specialty diagnostics with a $150 target, citing the Guardant360, Reveal, and Shield trio. Bernstein re‑entered with an Outperform and a $175 target, while Guggenheim raised its target to $160. When that many firms cluster between roughly $150 and $185, traders pay attention — and they trade the range.

Conclusion

For active traders, Guardant Health is a classic high‑beta, catalyst‑driven setup. GH combines a strong news engine — the new FDA Guardant360 CDx approval and companion role with HERNEXEOS — with a crowded bull camp on the Street. Price targets from RBC, Mizuho, Goldman Sachs, Evercore, Wolfe, Bernstein, and Guggenheim now stack well above recent trading levels, giving GH a thick band of perceived upside that momentum traders love to trade around.

At the same time, the financials remind everyone this is still a work‑in‑progress business. GH posted about $301.7M in quarterly revenue in Q1 2026 but burned cash, with operating cash flow around -$65.6M and free cash flow near -$71.2M. Losses are real, yet so is the nearly $1.1B cash and short‑term investments cushion. The bet the Street is making is simple: rising Guardant360 volumes, better pricing, Reveal and Shield adoption, and a growing MRD franchise will push that cash burn toward breakeven over time.

Traders also have to respect the other side of the tape. Co‑CEO Helmy Eltoukhy’s 100,000‑share sale (~$12.6M) in 2026/06, alongside a smaller sale by director Musa Tariq, shows insiders taking some chips off the table while still maintaining sizable holdings. Moves like that do not kill a bull thesis, but they are a reminder to stay disciplined.

As Tim Sykes loves to say, “The market doesn’t care about your opinion, only your preparation.” As millionaire penny stock trader and teacher Tim Sykes, says, “The goal is not to win every trade but to protect your capital and keep moving forward.” Guardant Health is giving the market plenty of catalysts; it’s on traders to study the chart, respect the volatility, and trade the plan — not the hype.

This is stock news, not investment advice. Timothy Sykes News delivers real-time stock market news focused on key catalysts driving short-term price movements. Our content is tailored for active traders and investors seeking to capitalize on rapid price fluctuations, particularly in volatile sectors like penny stocks. Readers come to us for detailed coverage on earnings reports, mergers, FDA approvals, new contracts, and unusual trading volumes that can trigger significant short-term price action. Some users utilize our news to explain sudden stock movements, while others rely on it for diligent research into potential investment opportunities.

Dive deeper into the world of trading with Timothy Sykes, renowned for his expertise in penny stocks. Explore his top picks and discover the strategies that have propelled him to success with these articles:

Once you’ve got some stocks on watch, elevate your trading game with StocksToTrade the ultimate platform for traders. With specialized tools for swing and day trading, StocksToTrade will guide you through the market’s twists and turns.
Dig into StocksToTrade’s watchlists here:

How much has this post helped you?

(0 votes, average: 0 out of 5)
Leave a reply

* Results are not typical and will vary from person to person. Making money trading stocks takes time, dedication, and hard work. There are inherent risks involved with investing in the stock market, including the loss of your investment. Past performance in the market is not indicative of future results. Any investment is at your own risk. See Terms of Service here

The available research on day trading suggests that most active traders lose money. Fees and overtrading are major contributors to these losses.

A 2000 study called “Trading is Hazardous to Your Wealth: The Common Stock Investment Performance of Individual Investors” evaluated 66,465 U.S. households that held stocks from 1991 to 1996. The households that traded most averaged an 11.4% annual return during a period where the overall market gained 17.9%. These lower returns were attributed to overconfidence.

A 2014 paper (revised 2019) titled “Learning Fast or Slow?” analyzed the complete transaction history of the Taiwan Stock Exchange between 1992 and 2006. It looked at the ongoing performance of day traders in this sample, and found that 97% of day traders can expect to lose money from trading, and more than 90% of all day trading volume can be traced to investors who predictably lose money. Additionally, it tied the behavior of gamblers and drivers who get more speeding tickets to overtrading, and cited studies showing that legalized gambling has an inverse effect on trading volume.

A 2019 research study (revised 2020) called “Day Trading for a Living?” observed 19,646 Brazilian futures contract traders who started day trading from 2013 to 2015, and recorded two years of their trading activity. The study authors found that 97% of traders with more than 300 days actively trading lost money, and only 1.1% earned more than the Brazilian minimum wage ($16 USD per day). They hypothesized that the greater returns shown in previous studies did not differentiate between frequent day traders and those who traded rarely, and that more frequent trading activity decreases the chance of profitability.

These studies show the wide variance of the available data on day trading profitability. One thing that seems clear from the research is that most day traders lose money .

Millionaire Media 66 W Flagler St. Ste. 900 Miami, FL 33130 United States (888) 878-3621 This is for information purposes only as Millionaire Media LLC nor Timothy Sykes is registered as a securities broker-dealer or an investment adviser. No information herein is intended as securities brokerage, investment, tax, accounting or legal advice, as an offer or solicitation of an offer to sell or buy, or as an endorsement, recommendation or sponsorship of any company, security or fund. Millionaire Media LLC and Timothy Sykes cannot and does not assess, verify or guarantee the adequacy, accuracy or completeness of any information, the suitability or profitability of any particular investment, or the potential value of any investment or informational source. The reader bears responsibility for his/her own investment research and decisions, should seek the advice of a qualified securities professional before making any investment, and investigate and fully understand any and all risks before investing. Millionaire Media LLC and Timothy Sykes in no way warrants the solvency, financial condition, or investment advisability of any of the securities mentioned in communications or websites. In addition, Millionaire Media LLC and Timothy Sykes accepts no liability whatsoever for any direct or consequential loss arising from any use of this information. This information is not intended to be used as the sole basis of any investment decision, nor should it be construed as advice designed to meet the investment needs of any particular investor. Past performance is not necessarily indicative of future returns.

Citations for Disclaimer

Barber, Brad M. and Odean, Terrance, Trading is Hazardous to Your Wealth: The Common Stock Investment Performance of Individual Investors. Available at SSRN: “Day Trading for a Living?”

Barber, Brad M. and Lee, Yi-Tsung and Liu, Yu-Jane and Odean, Terrance and Zhang, Ke, Learning Fast or Slow? (May 28, 2019). Forthcoming: Review of Asset Pricing Studies, Available at SSRN: “https://ssrn.com/abstract=2535636”

Chague, Fernando and De-Losso, Rodrigo and Giovannetti, Bruno, Day Trading for a Living? (June 11, 2020). Available at SSRN: “https://ssrn.com/abstract=3423101”